NASDAQ:SDGR Schrödinger (SDGR) Stock Price, News & Analysis $24.46 -1.14 (-4.45%) As of 03:28 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Schrödinger Stock (NASDAQ:SDGR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Schrödinger alerts:Sign Up Key Stats Today's Range$23.57▼$25.5850-Day Range$17.97▼$26.5452-Week Range$16.60▼$28.47Volume1.41 million shsAverage Volume817,686 shsMarket Capitalization$1.79 billionP/E RatioN/ADividend YieldN/APrice Target$33.00Consensus RatingBuy Company OverviewSchrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.Read More… Remove Ads Schrödinger Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreSDGR MarketRank™: Schrödinger scored higher than 46% of companies evaluated by MarketBeat, and ranked 442nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSchrödinger has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSchrödinger has only been the subject of 2 research reports in the past 90 days.Read more about Schrödinger's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Schrödinger are expected to grow in the coming year, from ($2.37) to ($2.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Schrödinger is -10.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Schrödinger is -10.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSchrödinger has a P/B Ratio of 3.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Schrödinger's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.03% of the float of Schrödinger has been sold short.Short Interest Ratio / Days to CoverSchrödinger has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in Schrödinger has recently increased by 5.06%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSchrödinger does not currently pay a dividend.Dividend GrowthSchrödinger does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.03% of the float of Schrödinger has been sold short.Short Interest Ratio / Days to CoverSchrödinger has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in Schrödinger has recently increased by 5.06%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.68 News SentimentSchrödinger has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Schrödinger this week, compared to 3 articles on an average week.Search Interest5 people have searched for SDGR on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows5 people have added Schrödinger to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Schrödinger insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $539,064.00 in company stock.Percentage Held by InsidersOnly 8.60% of the stock of Schrödinger is held by insiders.Percentage Held by Institutions79.05% of the stock of Schrödinger is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Schrödinger's insider trading history. Receive SDGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Schrödinger and its competitors with MarketBeat's FREE daily newsletter. Email Address SDGR Stock News HeadlinesSchrödinger, Inc. (NASDAQ:SDGR) Insider Karen Akinsanya Sells 16,723 SharesApril 16 at 4:44 AM | insidertrades.comKaren Akinsanya von Schrodinger verkauft Aktien im Wert von 419.570 US-DollarApril 15 at 9:15 PM | de.investing.comFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money isn't legally yours. Now, think your savings are safe? Think again.April 16, 2025 | Priority Gold (Ad)Schrodinger issues statement on FDA phasing out animal testing requirementApril 15 at 9:15 PM | markets.businessinsider.comSchrödinger unterstützt FDA-Initiative zur Reduzierung von TierversuchenApril 14 at 4:52 PM | de.investing.comSchrödinger’s Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other DrugsApril 14 at 11:51 AM | finance.yahoo.comSchrödinger's Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other DrugsApril 14 at 8:00 AM | businesswire.comSchrödinger (NASDAQ:SDGR) Shares Gap Up - Here's WhyApril 13 at 2:49 AM | americanbankingnews.comSee More Headlines SDGR Stock Analysis - Frequently Asked Questions How have SDGR shares performed this year? Schrödinger's stock was trading at $19.29 at the start of the year. Since then, SDGR stock has increased by 28.9% and is now trading at $24.86. View the best growth stocks for 2025 here. How were Schrödinger's earnings last quarter? Schrödinger, Inc. (NASDAQ:SDGR) released its quarterly earnings data on Wednesday, February, 26th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.20. The firm earned $88.32 million during the quarter, compared to analyst estimates of $83.20 million. Schrödinger had a negative net margin of 91.84% and a negative trailing twelve-month return on equity of 35.77%. Read the conference call transcript. When did Schrödinger IPO? Schrödinger (SDGR) raised $150 million in an IPO on Thursday, February 6th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Securities, Jefferies and BMO Capital Markets acted as the underwriters for the IPO. Who are Schrödinger's major shareholders? Schrödinger's top institutional investors include GAMMA Investing LLC (0.17%), Avanza Fonder AB (0.04%), IMC Chicago LLC and Greenwood Capital Associates LLC (0.03%). Insiders that own company stock include Ramy Farid, Kenneth Patrick Lorton, Geoffrey Craig Porges, Karen Akinsanya, Margaret Dugan, Yvonne Tran, Jenny Herman, Robert Lorne Abel and Nancy Thornberry. View institutional ownership trends. How do I buy shares of Schrödinger? Shares of SDGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Schrödinger own? Based on aggregate information from My MarketBeat watchlists, some other companies that Schrödinger investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings2/26/2025Today4/16/2025Next Earnings (Estimated)4/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SDGR CIK1490978 Webwww.schrodinger.com Phone212-295-5800FaxN/AEmployees790Year FoundedN/APrice Target and Rating Average Stock Price Target$32.29 High Stock Price Target$45.00 Low Stock Price Target$27.00 Potential Upside/Downside+26.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$40.72 million Net Margins-91.84% Pretax Margin-92.05% Return on Equity-35.77% Return on Assets-24.51% Debt Debt-to-Equity RatioN/A Current Ratio4.11 Quick Ratio4.11 Sales & Book Value Annual Sales$207.54 million Price / Sales9.01 Cash Flow$0.68 per share Price / Cash Flow37.42 Book Value$7.60 per share Price / Book3.37Miscellaneous Outstanding Shares73,038,000Free Float66,593,000Market Cap$1.87 billion OptionableOptionable Beta1.77 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:SDGR) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Schrödinger, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Schrödinger With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.